Chemokine, Fred Hutchinson researchers to investigate CTCE-0214 blood stem cells

By Elaine Rigoli

Tampa, Fla., June 21 - Chemokine Therapeutics Corp. has entered into an agreement with Fred Hutchinson Cancer Research Center in Seattle to study the company's hematological support compound, CTCE-0214.

Researchers at the Hutchinson Center will study the benefits of CTCE-0214, an agonist of the chemokine receptor CXCR4, in a series of preclinical studies investigating the drug's ability to accelerate the repopulation of stem cells to the bone marrow from human umbilical cord blood.

In addition to determining the quantity of stem cell expansion, the researchers will also examine the level of engraftment of these cells in a preclinical transplant model.

The planned studies would further establish the effects of the addition of CTCE-0214 to the currently available techniques and explore the potential use in a future human clinical setting, the company said in a news release.

The capacity of cord blood to treat cancer and a wide range of degenerative diseases is a growing area of interest but is limited by the quantity and quality of stem cells in cord blood.

CTCE-0214, based on Chemokine's preclinical research, mimics the activity of the natural chemokine SDF-1 by increasing the level of white blood cells (neutrophils), bleeding prevention cells (platelets) and stem cells (primitive blood forming cells) in the blood, the release said.

The company recently announced the completion of the first of its phase 1 clinical trial tests.

The company confirmed that the positive safety profile and efficacy results from the phase 1 trial of CTCE-0214 warranted the accelerated development of the product.

Chemokine is a biotechnology company located in Vancouver, B.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.